Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126450521 | 12645052 | 1 | I | 201304 | 20160309 | 20160811 | 20160811 | PER | NO-PFIZER INC-3211424 | PFIZER | 51.00 | YR | F | Y | 0.00000 | 20160811 | CN | NO | NO |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126450521 | 12645052 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | 3 TREATMENTS | U | UNK | 76517 | SOLUTION FOR INJECTION | ||||||||
| 126450521 | 12645052 | 2 | SS | VINORELBINE TARTRATE. | VINORELBINE TARTRATE | 1 | 3 TREATMENTS | U | UNK | 76827 | SOLUTION FOR INJECTION | ||||||||
| 126450521 | 12645052 | 3 | SS | AFATINIB | AFATINIB | 1 | UNK | U | UNK | 0 | |||||||||
| 126450521 | 12645052 | 4 | SS | AFATINIB | AFATINIB | 1 | UNK | U | 0 | ||||||||||
| 126450521 | 12645052 | 5 | SS | GEFITINIB | GEFITINIB | 1 | UNK | U | UNK | 0 | |||||||||
| 126450521 | 12645052 | 6 | SS | GEFITINIB | GEFITINIB | 1 | UNK | U | UNK | 0 | |||||||||
| 126450521 | 12645052 | 7 | SS | GEFITINIB | GEFITINIB | 1 | UNK | U | UNK | 0 | |||||||||
| 126450521 | 12645052 | 8 | SS | PEMETREXED | PEMETREXED | 1 | 5 TREATMENTS | U | UNK | 0 | |||||||||
| 126450521 | 12645052 | 9 | SS | OSIMERTINIB | OSIMERTINIB | 1 | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126450521 | 12645052 | 1 | Lung adenocarcinoma |
| 126450521 | 12645052 | 2 | Lung adenocarcinoma |
| 126450521 | 12645052 | 3 | Lung adenocarcinoma |
| 126450521 | 12645052 | 5 | Lung adenocarcinoma |
| 126450521 | 12645052 | 8 | Lung adenocarcinoma |
| 126450521 | 12645052 | 9 | Lung adenocarcinoma |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126450521 | 12645052 | Blood creatinine increased | |
| 126450521 | 12645052 | Chest pain | |
| 126450521 | 12645052 | Diarrhoea | |
| 126450521 | 12645052 | Disease progression | |
| 126450521 | 12645052 | Disease recurrence | |
| 126450521 | 12645052 | Drug intolerance | |
| 126450521 | 12645052 | Flatulence | |
| 126450521 | 12645052 | Gene mutation | |
| 126450521 | 12645052 | Hyperplasia | |
| 126450521 | 12645052 | Lung neoplasm | |
| 126450521 | 12645052 | Mouth ulceration | |
| 126450521 | 12645052 | Onychoclasis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126450521 | 12645052 | 1 | 201111 | 0 | ||
| 126450521 | 12645052 | 2 | 201111 | 0 | ||
| 126450521 | 12645052 | 3 | 20150408 | 0 | ||
| 126450521 | 12645052 | 4 | 20150427 | 0 | ||
| 126450521 | 12645052 | 5 | 20120130 | 0 | ||
| 126450521 | 12645052 | 6 | 20130101 | 0 | ||
| 126450521 | 12645052 | 7 | 20140101 | 0 | ||
| 126450521 | 12645052 | 8 | 20141128 | 0 | ||
| 126450521 | 12645052 | 9 | 20150821 | 0 |